NCT00690560View on ClinicalTrials.gov

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

October 31, 2010

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

prednisone

DRUG

vincristine sulfate

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Trial Locations (1)

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Centre Antoine Lacassagne

OTHER

NCT00690560 - Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter